The pharmaceutical company Glaxosmithkline, GSK, has received approval in China for the cancer drug Blenrep in combination treatment for patients with multiple myeloma that has relapsed or not responded to previous treatment.
ANNONS
Study data show, among other things, a 42 percent reduced risk of death and clearly improved progression-free survival compared with alternative treatment.
The drug is administered in outpatient care and targets a new mechanism of action.
”Patients with multiple myeloma who suffer a relapse need treatment options that are both effective and accessible. Today's approval of Blenrep means that patients in China with relapsed or refractory multiple myeloma in 2L+ get access to anti-BCMA therapy, which introduces a differentiated mechanism of action with the potential to help slow the course of the disease and prolong survival. In addition, Blenrep, as the only anti-BCMA-ADC drug, is fully administrable in outpatient care, which means that patients can be treated at any care facility without complex preparation before administration or hospital admission”, says Hesham Abdullah, global head of oncology in research and development at GSK.
The number of new cases per year is around 30,000 in China and mortality has increased by 50 percent for the disease over the past three decades.
